SARS-CoV-2 animal results further extend the robust in vivo data package that shows statistically and clinically significant efficacy of BIT225 in both treatment and prevention in murine models of COVID-19. Reducing the level of virus by more than 99.99% compared to controls.
The FDA recommends a small, placebo-controlled, proof-ofconcept, dose-finding study, with agreed end points. This design is de-risking and will provide the Company with important time and resource savings.
Please tell us how many trials from 2011 - 2020 in your fancy graph from the web have this background?
Ann: POSITIVE FDA GUIDANCE FOR COVID-19 CLINICAL PROGRAM, page-230
-
- There are more pages in this discussion • 243 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
